DTU Logo
About the DTU | News | Staff | Contact/Find us

AFORRD Study commences recruitment


The Atorvastatin in Factorial with Omega-3 fatty acids Risk Reduction in Diabetes (AFORRD) study began recruiting participants on Monday 1st November 2004. AFORRD is assessing the degree to which a statin and/or omega-3 fatty acids are likely to reduce coronary heart disease (CHD) risk in people with Type 2 diabetes. This 1000 patient, one-year study is being conducted by the Diabetes Trials Unit in an academic collaboration with Pfizer UK.